View Item 

Show simple item record

The Role of Tumor Necrosis Factor and Interleukin 1 in the Immunoinflammatory Response

dc.contributor.authorLarrick, James W.en_US
dc.contributor.authorKunkel, Steven L.en_US
dc.date.accessioned2006-09-08T19:20:52Z
dc.date.available2006-09-08T19:20:52Z
dc.date.issued1988-03en_US
dc.identifier.citationLarrick, James W.; Kunkel, Steven L.; (1988). "The Role of Tumor Necrosis Factor and Interleukin 1 in the Immunoinflammatory Response." Pharmaceutical Research 5(3): 129-139. <http://hdl.handle.net/2027.42/41520>en_US
dc.identifier.issn1573-904Xen_US
dc.identifier.issn0724-8741en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41520
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3072553&dopt=citationen_US
dc.description.abstractMonocytes and tissue macrophages produce at least two groups of protein mediators of inflammation, interleukin 1 (IL-1) and tumor necrosis factor (TNF). Recent studies have emphasized that TNF and IL-1 modulate the inflammatory function of endothelial cells, leukocytes, and fibroblasts. Although these cytokines share a number of biologic properties, they have quite distinct gene and protein structures. It is our purpose to focus on the role of these mediators in inflammation.en_US
dc.format.extent2044196 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherInflammationen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherInterleukin 1en_US
dc.subject.otherPharmacyen_US
dc.subject.otherMedical Lawen_US
dc.subject.otherTumor Necrosis Factoren_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.titleThe Role of Tumor Necrosis Factor and Interleukin 1 in the Immunoinflammatory Responseen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationotherDepartment of Immunology, Cetus Corp, and Psoriasis Research Institute, Palo Alto, California, 94303; GENELABS Inc, 505 Penobscot Dr, Redwood City, CA, 94062en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid3072553en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41520/1/11095_2004_Article_306156.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1015904721223en_US
dc.identifier.sourcePharmaceutical Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
11095_2004_Article_306156.pdf
Size:
1.949MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.